NCT04156139

Brief Summary

High-flow nasal cannula oxygen therapy(HFNC) has proved no significant difference compared with noninvasive positive pressure ventilation (NPPV) in preventing postextubation respiratory failure and reintubation in patients with acute hypoxemic respiratory failure.However, the efficacy of early postextubation sequential HFNC in COPD patients with hypercapnic respiratory failure is inconclusive.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
502

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 1, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

November 7, 2019

Completed
1 month until next milestone

Study Start

First participant enrolled

December 18, 2019

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2022

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2022

Completed
Last Updated

January 23, 2020

Status Verified

January 1, 2020

Enrollment Period

2.4 years

First QC Date

November 1, 2019

Last Update Submit

January 22, 2020

Conditions

Keywords

NPPVHFNCWeaningCOPDPIC

Outcome Measures

Primary Outcomes (1)

  • reintubation

    The primary outcome is reintubation within the 7 days after extubation.

    within the 7 days after extubation.

Secondary Outcomes (1)

  • Weaning failure

    within the7 days after extubation

Study Arms (2)

Control group

ACTIVE COMPARATOR

NPPV treatment for patients will be performed for patients immediately after extubation in control group.

Device: HFNCDevice: NPPV

intervention group

EXPERIMENTAL

HFNC treatment will be performed for patients immediately after extubation in the intervention group.

Device: HFNCDevice: NPPV

Interventions

HFNCDEVICE

The gas flow rate was set at 45\~55 L/min. The inhaled oxygen concentration will be dynamically adjusted to maintain SpO2 ≥ 92%. The temperature will be set at 37 °C.

Control groupintervention group
NPPVDEVICE

The PEEP is initially set as 5 cm H2O, the inspiratory pressure is 10 cm H2O, and the target tidal volume is 6-8 ml/kg.

Control groupintervention group

Eligibility Criteria

Age40 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \. COPD patients with bronchopulmonary infection 2. Patients with hypercapnia respiratory failure treated with invasive mechanical 3.14 days ≥ invasive mechanical ventilation ≥ 48 hours; 4.Reached the pulmonary infection control (PIC) window; 5.Have self-care ability with oxygen supply during stable phrase

You may not qualify if:

  • Severe organ dysfunction;Myopathy or myasthenia gravis;Upper airway obstruction;A large amount of secretions and inability to drain;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, 100853, China

RECRUITING

MeSH Terms

Conditions

Pulmonary Disease, Chronic ObstructiveRespiratory Insufficiency

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsRespiration Disorders

Study Officials

  • XIE Lixin, MD

    Chinese PLA General Hospital

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Department of Respiratory and Critical Care Medicine, Chinese PLA General Hospital

Study Record Dates

First Submitted

November 1, 2019

First Posted

November 7, 2019

Study Start

December 18, 2019

Primary Completion

May 1, 2022

Study Completion

November 1, 2022

Last Updated

January 23, 2020

Record last verified: 2020-01

Data Sharing

IPD Sharing
Will not share

Locations